Your email has been successfully added to our mailing list.

×
-0.000172637030643039 -0.00021579628830389 0.000690548122572277 0.00155373327578759 0.00267587397496765 0.0056107034958998 0.00448856279671986 0.00276219249028911
Stock impact report

Lilly cancer drug fails key trial, will no longer be prescribed [Reuters]

Eli Lilly and Company (LLY) 
Last eli lilly and company earnings: 4/23 06:25 am Check Earnings Report
US:NYSE Investor Relations: investor.lilly.com
Company Research Source: Reuters
Lilly cancer drug fails key trial, will no longer be prescribed | Reuters 3 Min Read (Reuters) - Eli Lilly and Co said on Friday that its cancer treatment Lartruvo, which had won conditional approval, failed to improve patient survival in a long-term confirmatory study and will no longer be prescribed, driving the drugmaker’s shares down nearly 3 percent. No new U.S. patients will be started on the drug and Lilly is suspending promotion of the medicine, the company said. Lartruvo won accelerated approval in 2016 in the United States and conditional approval in Europe based on results from a promising mid-stage trial. But its continued approval was contingent on the results of a larger, late-stage trial confirming the drug’s benefits. On Friday, Lilly said Lartruvo combined with the standard-of-care chemotherapy doxorubicin did not prolong survival more than doxorubicin alone in patients with advanced soft tissue sarcoma. Lilly oncology chief Anne White said in a phone interview the re Show less Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
LLY alerts

from News Quantified
Opt-in for
LLY alerts

from News Quantified